• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Chudnovsky Yekaterina converted options into 3,500,573 shares (SEC Form 4)

    3/7/25 4:06:57 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Chudnovsky Yekaterina

    (Last) (First) (Middle)
    C/O ELICIO THERAPEUTICS, INC.
    451 D STREET, 5TH FLOOR, SUITE 501

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Elicio Therapeutics, Inc. [ ELTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/05/2025 C 3,500,573 A $5.81 5,416,212 I Held by GKCC, LLC(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Convertible Note (convertible into Common Stock) $5.81 03/05/2025 C 3,442,341 (2) (2) Common Stock 3,442,341 $5.81 0 I Held by GKCC, LLC(1)
    1. Name and Address of Reporting Person*
    Chudnovsky Yekaterina

    (Last) (First) (Middle)
    C/O ELICIO THERAPEUTICS, INC.
    451 D STREET, 5TH FLOOR, SUITE 501

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    GKCC, LLC

    (Last) (First) (Middle)
    501 SILVERSIDE ROAD, SUITE 87AVA

    (Street)
    WILMINGTON DE 19809

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.
    2. The Convertible Note had a stated maturity date of February 15, 2026. The Convertible Note, including any accrued but unpaid interest, was converted into shares of Common Stock on March 5, 2025 at a conversion price of $5.81 per share.
    /s/ Yekaterina Chudnovsky 03/06/2025
    /s/ Yekaterina Chudnovsky, Manager GKCC, LLC 03/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ELTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Interim analysis focused on disease-free survival ("DFS") in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025 Company has alignment with U.S. Food and Drug Administration ("FDA") on key design elements of planned Phase 3 study of ELI-002 Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025, and provided recent corpo

      5/13/25 4:05:00 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

      BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on April 15, 2025, Elicio granted inducement awards to Elicio's newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two additional new employees, as an inducement material to Dr. Shah and such employees entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4), which grants were approved by the compensation committee of Elicio's board of directors in accordance with the Elicio 2024 Induceme

      4/16/25 4:05:00 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

      Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival ("DFS") event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration ("FDA") on key elements of planned ELI-002 Phase 3 study design, including dose, patient population and primary endpoint analysis Strengthened cash position to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results f

      3/31/25 7:00:00 AM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELTX
    SEC Filings

    See more
    • Elicio Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

      5/20/25 8:06:34 AM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Elicio Therapeutics Inc.

      10-Q - Elicio Therapeutics, Inc. (0001601485) (Filer)

      5/13/25 4:31:41 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elicio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

      5/13/25 4:27:01 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

      BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof. Dr. Shah brings a wealth of leadership experience to Elicio after previously serving as chief financial officer, chief business officer, and in other senior leadership roles at multiple publicly traded biotechnology companies. "We are pleased to welcome Preetam to Elicio's executive team," said Robert Connelly, Ph.D., Preside

      3/24/25 7:00:00 AM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics

      BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics. Ms. Filoon will oversee all company legal affairs including corporate governance and compliance functions. Dr. Kheoh will provide biostatistical leadership and strategic guidance into the development of the Company's product candidate portfolio including the ongoing AMPLIFY-201 and AMPLIFY-7P trials of the lead asset, ELI-002. "Megan and Thian are joining us at an exc

      8/28/23 8:00:00 AM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ashe Carol Gail

      4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

      5/20/25 4:08:00 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Nissenson Allen

      4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

      5/20/25 4:07:35 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Venkatesan Jay

      4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

      5/20/25 4:07:13 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Elicio Therapeutics Inc.

      SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

      8/14/24 5:01:49 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Elicio Therapeutics Inc.

      SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

      7/2/24 4:39:47 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Elicio Therapeutics Inc. (Amendment)

      SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

      4/10/24 4:01:50 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care